Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
304 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06508684 | Current Status of BTKi Treatment for CLL/SLL in China | unknown | — | 1,000 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 18, 2024 | clinicaltrials |
| NCT06504875 | Application of PD-1 Monoclonal Antibody in Combination With IL-2 and CapeOX in Organ Preservation Therapy for Ultra-Low Localized Advanced Rectal Cancer | not yet recruiting | — | 23 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER |
| 0 |
| Jul 17, 2024 |
| clinicaltrials |
| NCT06504901 | Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases | not yet recruiting | — | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Jul 17, 2024 | clinicaltrials |
| NCT06503211 | On the Safety, Tolerability, and Efficacy of UTAA09 Injection in the Treatment of Lymphoma | unknown | Phase 1 | 10 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06504017 | FUS-TB VS COG-TB in Small Lesions of Prostate Cancer | unknown | N/A | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Jul 16, 2024 | clinicaltrials |
| NCT06472479 | LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma | not yet recruiting | N/A | 66 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT06477718 | Genomic Signatures for Patients With Initially Unresectable Colorectal Liver Metastases | completed | — | 286 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Jun 27, 2024 | clinicaltrials |
| NCT06470633 | To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer | not yet recruiting | Phase 2 | 29 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Jun 24, 2024 | clinicaltrials |
| NCT06467565 | NALIRIFOX as Induction Therapy in LAPC | unknown | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT06385873 | RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer | not yet recruiting | Phase 2 | 32 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | May 13, 2024 | clinicaltrials |
| NCT05950997 | A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL | recruiting | N/A | 89 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06394791 | Evaluation of The Efficacy And Safety of PD-1 + IL-2 Combined With Capox Treatment After Loop Colostomy Surgery in Left-sided Colorectal Cancer Patients Complicating Acute Obstruction | unknown | Phase 1 / Phase 2 | 27 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | May 1, 2024 | clinicaltrials |
| NCT06383078 | HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer | not yet recruiting | Phase 2 | 120 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Apr 25, 2024 | clinicaltrials |
| NCT05659056 | Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer | unknown | Phase 2 | 65 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT06125834 | Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy | unknown | Phase 2 | 36 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT06360471 | Fertility Preservation and Pregnancy and Offspring Health Outcomes in Female Cancer | recruiting | — | 2,800 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT06362330 | Multi-parametric MRI in Patients of Bladder Cancer | unknown | — | 1,000 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06241326 | Immunotherapy for Hepatocellular Carcinoma(IFHC) | recruiting | — | 11,000 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT06354218 | Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age | recruiting | Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06350825 | Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients | recruiting | Phase 3 | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 5, 2024 | clinicaltrials |
| NCT06341595 | Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM | recruiting | Phase 2 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06341894 | Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer | recruiting | Phase 2 | 1,163 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06287541 | The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral Resection | recruiting | N/A | 428 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT06288620 | Microwave Ablation in the Treatment of Early-stage Unifocal Invasive Breast Cancer | unknown | N/A | 77 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT06041425 | The Effects of Oxycodone Versus Sufentanil on Pain and Inflammatory Response After TACE | completed | Phase 4 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06279767 | Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma | unknown | Phase 1 / Phase 2 | 27 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06234150 | Aerobic Dance During Chemotherapy in Breast Cancer Patients With Cognitive Impairment(ADANC) | not yet recruiting | N/A | 90 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06253091 | Comparison of the Application of Robot-assisted Laparoscopic Pathways in Radical Cystectomy | unknown | N/A | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06254690 | The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study | recruiting | Phase 2 | 102 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT06238193 | Molecular Characteristics of Early-onset Compared With Late-onset Colorectal Cancer | completed | — | 11,344 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Feb 2, 2024 | clinicaltrials |
| NCT06232694 | Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML | recruiting | N/A | 54 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT06220305 | DNA Methylation Combined With Artificial Intelligence Imaging to Identify Lung Nodules(MAGIC) | unknown | — | 100 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT06211881 | Chi-GVM Regimen for the Treatment of R/R PTCL | unknown | N/A | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT04805736 | Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer | completed | Phase 2 | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT06177015 | Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC | recruiting | Phase 3 | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT06001086 | A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer | recruiting | Phase 2 | 70 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT06168227 | A Multicenter and Real-world Analysis of RC48-ADC in Patients With HER2-positive or HER2-low Expressing, Locally Advanced or Metastatic Breast Cancer | completed | — | 150 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT06153368 | Cadonilimab Plus mFOLFIRINOX as Conversion Therapy in LAPC | unknown | Phase 2 | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT06130644 | Early Lymph Node Metastasis in T1/2 Stage Colorectal Cancer: Molecular and Clinical Insights | completed | — | 1,451 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Nov 14, 2023 | clinicaltrials |
| NCT06124729 | Evaluation of the Efficacy and Safety of Bevacizumab Combined With PD-1 Monoclonal Antibody in Preoperative Neoadjuvant Therapy for MSS Colorectal Cancer With Liver Metastases | unknown | — | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Nov 9, 2023 | clinicaltrials |
| NCT05494060 | XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma(EXPLORING) | recruiting | Phase 2 | 80 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT06104267 | Medical Tai Chi Exercise Healing in Treating mCRC Patients | unknown | N/A | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT06060704 | Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC. | unknown | Phase 2 | 33 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT06054685 | Association Between Body Composition and Digestive System Cancer Survival | unknown | — | 100 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT06048926 | Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma | enrolling by invitation | N/A | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05823623 | Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer | unknown | Phase 2 | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT06037655 | Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC(Modified) | not yet recruiting | Phase 2 | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Sep 14, 2023 | clinicaltrials |
| NCT06015464 | An Ambispective Cohort Study of Orelabrutinib in Combination With Standard Treatment Regimen for Untreated DLBCL | unknown | — | 81 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT06010212 | Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma | unknown | Phase 1 / Phase 2 | 36 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Aug 24, 2023 | clinicaltrials |
| NCT05513638 | Artificial Intelligence-Based Computer-Aided Diagnosis of Prostate Cancer | unknown | — | 2,000 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 21, 2023 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials